Clinical Trial Update: A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) [Phase 3]

View source ↗

Summary

This update notes that Merck's MK-8527 is being evaluated in a Phase 3 trial to prevent HIV-1 infection (as HIV pre-exposure prophylaxis) and is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• MK-8527

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | Status: RECRUITING